{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:09:06Z","timestamp":1778324946372,"version":"3.51.4"},"reference-count":62,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1507 leadership and the data safety monitoring board (DSMB) established incremental entry criteria for children aged 5 to 14.99 years with sickle cell disease (SCD) enrolling in a phase 2 trial of HLA-haploidentical hematopoietic stem cell transplantation. First, the enrollment was limited to overt stroke in the first 10 participants (stage 4). Subsequently, the DSMB reviewed the interim results and expanded the eligibility to include children with silent cerebral infarcts or abnormal transcranial Doppler velocities with magnetic resonance angiography\u2013defined cerebral vasculopathy (stage 3). A third cohort was enrolled after the DSMB reviewed the clinical outcomes in these cumulative initial enrollments (n\u00a0=\u00a018) and additions were made to the entry criteria that included nonneurologic morbidities (stage 2). Added eligibility criteria included the following: (1) life-threatening acute chest syndrome requiring exchange transfusion; (2) right heart catheterization confirmed pulmonary hypertension; (3) persistent systemic hypertension despite maximum medical therapy; (4) acute pain despite maximum medical therapy in the absence of psychosocial factors and unmanaged asthma after adjudication; and (5) 2 major priapism episodes in 12\u00a0months or 3 in 24\u00a0months. Children with SCD who did not meet the criteria for stages 4, 3, and 2 were not eligible. To our knowledge, for the first time, we introduce a staged strategy for eligibility in a curative therapy trial for children with SCD concordant with 45 Code of Federal Regulations \u00a7 46.405(b). The research governance\u2013mandated eligibility strategy used within the BMT CTN 1507 phase 2 study may apply to future pediatric SCD curative therapy trials. This trial was registered at www.ClinicalTrials.gov as #NCT032635590.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014078","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T21:59:47Z","timestamp":1728338387000},"page":"6055-6063","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-3559","authenticated-orcid":false,"given":"Tami D.","family":"John","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University, Palo Alto, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6515-4559","authenticated-orcid":false,"given":"Mark C.","family":"Walters","sequence":"additional","affiliation":[{"name":"2Hematology Division, Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-2920","authenticated-orcid":false,"given":"Hemalatha G.","family":"Rangarajan","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahvish Q.","family":"Rahim","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Oncology, and Stem Cell Transplant, Riley Hospital for Children, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-435X","authenticated-orcid":false,"given":"Christopher","family":"McKinney","sequence":"additional","affiliation":[{"name":"5Department of Hematology\/Oncology, Children\u2019s Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, Center for Cancer and Immunotherapy Research, Children\u2019s National Hospital and The George Washington University, Washington D.C."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada","family":"Abusin","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, C.S. Mott Children\u2019s Hospital, University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-4243","authenticated-orcid":false,"given":"Mary","family":"Eapen","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adetola A.","family":"Kassim","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Division of Hematology\/Oncology, Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-1604","authenticated-orcid":false,"given":"Michael R.","family":"DeBaun","sequence":"additional","affiliation":[{"name":"10Department of Pediatrics, Division of Hematology\/Oncology, Vanderbilt-Meharry Sickle Cell Disease Center of Excellence, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"8","key":"2024121014061574000_bib1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2024121014061574000_bib2","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1182\/blood-2014-09-551564","article-title":"How I treat and manage strokes in sickle cell disease","volume":"125","author":"Kassim","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2024121014061574000_bib3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbmt.2013.02.010","article-title":"Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease","volume":"19","author":"Dallas","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"2024121014061574000_bib4","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2024121014061574000_bib5","first-page":"118","article-title":"Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO","volume":"12","author":"Bernaudin","year":"1993","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024121014061574000_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jama.2018.20059","article-title":"Association of matched sibling donor hematopoietic stem cell transplantation with transcranial Doppler velocities in children with sickle cell anemia","volume":"321","author":"Bernaudin","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"2024121014061574000_bib7","first-page":"1918","article-title":"Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease","volume":"95","author":"Walters","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2024121014061574000_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024121014061574000_bib9","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"key":"2024121014061574000_bib10","doi-asserted-by":"crossref","first-page":"846596","DOI":"10.3389\/fneur.2022.846596","article-title":"Incidence, kinetics, and risk factors for intra- and extracranial cerebral arteriopathies in a newborn sickle cell disease cohort early assessed by transcranial and cervical color Doppler ultrasound","volume":"13","author":"Bernaudin","year":"2022","journal-title":"Front Neurol"},{"issue":"8","key":"2024121014061574000_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1401731","article-title":"Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia","volume":"371","author":"DeBaun","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024121014061574000_bib12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2010-01-261123","article-title":"Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease","volume":"117","author":"Hulbert","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2024121014061574000_bib13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.25085","article-title":"Children with sickle cell anemia with normal transcranial Doppler ultrasounds and without silent infarcts have a low incidence of new strokes","volume":"93","author":"Jordan","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"2024121014061574000_bib14","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1182\/blood-2003-06-1972","article-title":"Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study","volume":"103","author":"Abboud","year":"2004","journal-title":"Blood"},{"issue":"13","key":"2024121014061574000_bib15","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/bloodadvances.2022009202","article-title":"Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries","volume":"7","author":"Jiao","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2024121014061574000_bib16","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024121014061574000_bib17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2024121014061574000_bib18","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/bloodadvances.2017007708","article-title":"The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia","volume":"1","author":"Fitzhugh","year":"2017","journal-title":"Blood Adv"},{"issue":"26","key":"2024121014061574000_bib19","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1182\/bloodadvances.2017007690","article-title":"Primum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ disease","volume":"1","author":"DeBaun","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"2024121014061574000_bib20","doi-asserted-by":"crossref","first-page":"E212","DOI":"10.1002\/ajh.23819","article-title":"Factors predicting future ACS episodes in children with sickle cell anemia","volume":"89","author":"DeBaun","year":"2014","journal-title":"Am J Hematol"},{"issue":"3","key":"2024121014061574000_bib21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/thx.2004.029165","article-title":"Asthma in children with sickle cell disease and its association with acute chest syndrome","volume":"60","author":"Knight-Madden","year":"2005","journal-title":"Thorax"},{"issue":"4","key":"2024121014061574000_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jpeds.2013.11.034","article-title":"Wheezing symptoms and parental asthma are associated with a physician diagnosis of asthma in children with sickle cell anemia","volume":"164","author":"Strunk","year":"2014","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"2024121014061574000_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1005565","article-title":"A\u00a0hemodynamic study of pulmonary hypertension in sickle cell disease","volume":"365","author":"Parent","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024121014061574000_bib24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2015-08-618561","article-title":"Pathophysiology and treatment of pulmonary hypertension in sickle cell disease","volume":"127","author":"Gordeuk","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2024121014061574000_bib25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/bmt.2015.11","article-title":"Traffic light: prognosis-based eligibility for clinical trials of hematopoietic SCT in adults with sickle cell anemia","volume":"50","author":"Rotz","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"2024121014061574000_bib26","doi-asserted-by":"crossref","first-page":"9636897211046559","DOI":"10.1177\/09636897211046559","article-title":"Hematopoietic stem cell transplant for sickle cell disease: PATIENT SELEction and timing based on sickle cell-related multiple chronic conditions","volume":"30","author":"Jang","year":"2021","journal-title":"Cell Transplant"},{"issue":"2","key":"2024121014061574000_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0002-9343(96)00407-X","article-title":"Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia","volume":"102","author":"Pegelow","year":"1997","journal-title":"Am J Med"},{"issue":"16","key":"2024121014061574000_bib28","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2011-05-349621","article-title":"Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure","volume":"119","author":"DeBaun","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2024121014061574000_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajh.21016","article-title":"Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency","volume":"83","author":"Gordeuk","year":"2008","journal-title":"Am J Hematol"},{"issue":"2","key":"2024121014061574000_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/bloodadvances.2020002948","article-title":"A\u00a0systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy","volume":"5","author":"Badawy","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2024121014061574000_bib31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/00043426-200211000-00008","article-title":"Home management of pain in sickle cell disease: a daily diary study in children and adolescents","volume":"24","author":"Dampier","year":"2002","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"1-2","key":"2024121014061574000_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.pain.2009.06.029","article-title":"Pain site frequency and location in sickle cell disease: the PiSCES project","volume":"145","author":"McClish","year":"2009","journal-title":"Pain"},{"issue":"6","key":"2024121014061574000_bib33","first-page":"461","article-title":"Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports","volume":"3","author":"Dampier","year":"2002","journal-title":"J\u00a0Pain"},{"issue":"8","key":"2024121014061574000_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ajh.21750","article-title":"Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and geographical location","volume":"85","author":"Ballas","year":"2010","journal-title":"Am J Hematol"},{"issue":"1","key":"2024121014061574000_bib35","first-page":"43","article-title":"The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA\/SMSNA guideline","volume":"208","author":"Bivalacqua","year":"2022","journal-title":"J\u00a0Urol"},{"issue":"14","key":"2024121014061574000_bib36","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1182\/bloodadvances.2020002062","article-title":"Men with sickle cell disease experience greater sexual dysfunction when compared with men without sickle cell disease","volume":"4","author":"Idris","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024121014061574000_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MPH.0000000000002056","article-title":"Psychometric impact of priapism on lives of adolescents and adults with sickle cell anemia: a sequential independent mixed-methods design","volume":"44","author":"Idris","year":"2022","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"3","key":"2024121014061574000_bib38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A\u00a0phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"2024121014061574000_bib39","unstructured":"US Department of Health and Human Services\n          . 45 CRF 46: Subpart D-additional protections for children involved as subjects in research. Accessed 16 November 2013. https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/regulations\/45-cfr-46\/common-rule-subpart-d\/index.html#46.4052023."},{"issue":"6","key":"2024121014061574000_bib40","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjh.14015","article-title":"Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines","volume":"173","author":"Couque","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2024121014061574000_bib41","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London","volume":"92","author":"Telfer","year":"2007","journal-title":"Haematologica"},{"issue":"15","key":"2024121014061574000_bib42","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1182\/bloodadvances.2022008692","article-title":"Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy","volume":"7","author":"Cronin","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2024121014061574000_bib43","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/pbc.25608","article-title":"Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment","volume":"62","author":"Le","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2024121014061574000_bib44","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2024121014061574000_bib45","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2015-05-644435","article-title":"Low forced expiratory volume is associated with earlier death in sickle cell anemia","volume":"126","author":"Kassim","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2024121014061574000_bib46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-115-8-614","article-title":"Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality","volume":"115","author":"Powars","year":"1991","journal-title":"Ann Intern Med"},{"issue":"3","key":"2024121014061574000_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High one year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br J Haematol"},{"issue":"12","key":"2024121014061574000_bib48","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1159\/000513012","article-title":"Mortality and hospitalizations among sickle cell disease patients with end-stage kidney disease initiating dialysis","volume":"51","author":"Olaniran","year":"2020","journal-title":"Am J Nephrol"},{"issue":"3","key":"2024121014061574000_bib49","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.hoc.2018.01.014","article-title":"Key components of pain management for children and adults with sickle cell disease","volume":"32","author":"Brandow","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"2024121014061574000_bib50","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s13023-021-02096-6","article-title":"A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease","volume":"16","author":"Zaidi","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2024121014061574000_bib51","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1464-410X.2002.03022.x","article-title":"Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study","volume":"90","author":"Adeyoju","year":"2002","journal-title":"BJU Int"},{"issue":"2","key":"2024121014061574000_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/03630269.2018.1452760","article-title":"Prevalence and characteristics of priapism in sickle cell disease","volume":"42","author":"Arduini","year":"2018","journal-title":"Hemoglobin"},{"issue":"7","key":"2024121014061574000_bib53","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ajh.25799","article-title":"Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: the PUSH study","volume":"95","author":"Nouraie","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"2024121014061574000_bib54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.mph.0000212968.98501.2b","article-title":"Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms","volume":"28","author":"Glassberg","year":"2006","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"20","key":"2024121014061574000_bib55","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024121014061574000_bib56","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1056\/NEJMoa2000146","article-title":"Hydroxyurea dose escalation for sickle cell anemia in Sub-Saharan Africa","volume":"382","author":"John","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024121014061574000_bib57","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S2352-3026(21)00368-9","article-title":"Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial","volume":"9","author":"Abdullahi","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"2024121014061574000_bib58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024121014061574000_bib59","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"142","author":"Frangoul","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2024121014061574000_bib60","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of lentiglobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10019","key":"2024121014061574000_bib61","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"issue":"10037","key":"2024121014061574000_bib62","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/S0140-6736(16)00145-8","article-title":"The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia","volume":"387","author":"DeBaun","year":"2016","journal-title":"Lancet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6055\/2345028\/blooda_adv-2024-014078-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6055\/2345028\/blooda_adv-2024-014078-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:09:06Z","timestamp":1733839746000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/23\/6055\/518099\/Incremental-eligibility-criteria-for-the-BMT-CTN"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":62,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014078","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}